GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » Beginning Cash Position

Karyopharm Therapeutics (FRA:25K) Beginning Cash Position : €67.2 Mil (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Beginning Cash Position?

Karyopharm Therapeutics's Beginning Cash Position for the quarter that ended in Jun. 2024 was €67.2 Mil.

Karyopharm Therapeutics's quarterly Beginning Cash Position increased from Dec. 2023 (€41.1 Mil) to Mar. 2024 (€48.9 Mil) and increased from Mar. 2024 (€48.9 Mil) to Jun. 2024 (€67.2 Mil).

Karyopharm Therapeutics's annual Beginning Cash Position increased from Dec. 2021 (€78.9 Mil) to Dec. 2022 (€186.4 Mil) but then declined from Dec. 2022 (€186.4 Mil) to Dec. 2023 (€125.5 Mil).


Karyopharm Therapeutics Beginning Cash Position Historical Data

The historical data trend for Karyopharm Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Beginning Cash Position Chart

Karyopharm Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.86 107.43 78.87 186.39 125.52

Karyopharm Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.96 76.69 41.12 48.94 67.22

Karyopharm Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Karyopharm Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Karyopharm Therapeutics Business Description

Traded in Other Exchanges
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics Headlines

No Headlines